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Posttranslational modifications of proteins are pivotal to the reg-
ulation of their physiological function. While modifications
involving phosphorylation and glycosylation have been well
studied, lipid modification is an emerging field that is at present
extensively investigated. In particular, prenylation, a lipid modifi-
cation with intermediates in the cholesterol biosynthesis path-
way, such as the 15-carbon farnesyl and the 20-carbon
geranylgeranyl, is of great interest because many prenylated
proteins are involved in signal transduction circuits whose dys-
function leads to cancer (Glomset et al., 1990; Sebti and Der,
2003; Zhang and Casey, 1996). There are 3 prenyltransferases:
farnesyltransferase (FTase), geranylgeranyltransferase I, and
geranylgeranyltransferase II (GGTase I and GGTase II).These 3
enzymes catalyze the covalent formation of a thioether bond
between the prenyl group and the thiol group of cysteines at the
carboxyl terminal of an estimated 300 proteins in the human
proteome. FTase and GGTase I prenylate proteins which con-
tain CAAX (C = cysteine, A = aliphatic, and X = any amino acid)
at their carboxyl terminus, with FTase preferring proteins with X
= Met, Ser, Ala, or Gln, and GGTase I preferring proteins with X
= leu or Ile. FTase and GGTase I are heterodimers that share an
α subunit and have homologous (30% amino acid identity) but
distinct β subunits (Zhang and Casey, 1996). GGTase II (also
known as RabGGTase) modifies proteins that usually end in
CXC. RabGGTase is also a heterodimer, with its α subunit hav-
ing 27% identity with the α subunit of FTase and GGTase I, and
the β subunit showing 29% identity to the β subunit of FTase
(Zhang and Casey, 1996).
Although a search of the Swiss-Prot database identified
about 300 proteins which terminate with a CXXX and which are
potentially prenylated (K. Zhu and S.M.S., unpublished data),
only a fraction of these have been shown to actually be preny-
lated. Among documented farnesylated proteins are H-, K-, and
N-Ras GDP/GTP binding GTPases, the nuclear lamins, and the
kinetechores CENP-E and F. Geranylgeranylated proteins
include the GTP/GDP binding GTPases, RhoA, RhoC, Rac1,
cdc-42, and R-Ras (Kho et al., 2004; Reid et al., 2004). RhoB is
found both farnesylated and geranylgeranylated in cells
(Armstrong et al., 1995), whereas K-Ras becomes geranylger-
anylated when FTase activity is blocked (Lerner et al., 1997;
Rowell et al., 1997; Whyte et al., 1997). The fact that farnesyla-
tion and geranylgeranylation are required for the ability of Ras
and Rho proteins to induce malignant transformation, invasion,
and metastasis prompted many investigators to develop FTase
inhibitors (FTIs) and GGTase I inhibitors (GGTIs) as novel anti-
cancer drugs (Cox and Der, 1997; Downward, 2003; Gibbs and
Oliff, 1997; Sebti and Der, 2003). To this end, many CAAX pep-
tidomimetics as well as other FTIs and GGTIs have been devel-
oped that are highly potent and selective at inhibiting FTase and
GGTase I in vitro and protein farnesylation and geranylgerany-
lation in intact cells. Furthermore, FTIs and GGTIs have been
shown to inhibit proliferation and induce apoptosis in various
biological systems. While GGTIs induce p21waf1, CDK inhibi-
tion, and Rb hypophosphorylation and arrest cells in the G1
phase of the cell division cycle (Sebti and Hamilton, 2000), FTIs
in most cell types induce accumulation at prometaphase during
mitosis (Ashar et al., 2000; Crespo et al., 2001).The antiprolifer-
ative and proapoptotic activity of FTIs appears to be related to
their ability to inhibit the PI3K/Akt, mTOR, S6 kinase, and/or
RheB pathways at least in some cancer cell lines (Castro et al.,
2003; Jiang et al., 2000; Law et al., 2000; Liu and Prendergast,
2000; Tamanoi et al., 2001). While GGTIs are also potent
inhibitors of this pathway, their ability to induce apoptosis may
require suppression of survivin expression as well as inhibition
of the PI3K/Akt pathway (Dan et al., 2004). Although these path-
ways appear to be involved in some human cancer cells, in oth-
ers, the mechanism by which FTIs and GGTIs inhibit tumor
growth and induce apoptosis is not known, and much more
investigation is warranted to enhance our understanding of how
these agents work. Finally, while many farnesylated proteins
such as Ras, RhoB, RheB, CENP-E, and CENP-F have been
proposed as targets for FTIs, direct proof that inhibition of the
farnesylation of these proteins is involved in the mechanism of
antitumor activity of FTIs is lacking (Prendergast, 2001; Sebti
and Der, 2003)
The outstanding antitumor activity and lack of toxicity of
FTIs in many animal models led to their quick approval for test-
ing clinically. The results of these clinical trials are mixed, with
positive outcomes in some settings such as in hematological
diseases and breast cancer, but not in others such as highly
metastatic advanced colon and pancreatic cancers (Adjei,
2001; Zhu et al., 2003). At present, it is not understood why
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nesylation include the fact that some farnesylated proteins may
become geranylgeranylated by GGTase I (e.g., K-Ras), that
alternative mechanisms to localize to cellular membranes could
exist (e.g., palmitoylation), and that alternative pathways, not
requiring farnesylated proteins, may accomplish the same
physiological functions. Regardless of the mechanism of com-
pensation, the fact that the lack of FTase activity has little affect
on adult homeostasis in mice gives further support for the safe
use of FTIs in humans, and is consistent with clinical trial results
where FTIs were found to be well tolerated in most patients at
doses where clinical activity is observed (Adjei, 2001).
Furthermore, the maturation defects in erythroid cells of adult
FTase β (−/−) mice are also consistent with some of the side
effects observed in FTI clinical trials (Adjei, 2001). The third
important observation made by Mijimolle et al. is that protein far-
nesylation is not required for lung tumorigenesis in a K-Ras-
dependent mouse model.This is not surprising, considering the
large body of evidence demonstrating that K-Ras is geranylger-
anylated by GGTase I when FTase is inhibited (Lerner et al.,
1997; Rowell et al., 1997; Whyte et al., 1997). If the observation
that K-Ras can induce lung tumors in the absence of protein far-
nesylation in mice can be extrapolated to humans, then lung
cancer patients with tumors where K-Ras drives oncogenesis
would most likely be resistant to FTIs. This reasoning is in
agreement with phase II clinical trials in lung cancer patients
where little clinical activity was seen (Adjei, 2001). The fourth
conclusion that can be drawn from this study is that protein far-
nesylation is not required for initiation but is very important for
tumor progression during chemical (DMBA + TPA) skin carcino-
genesis. This suggests that farnesylated proteins are not
required for the initial “hit” that converts cells from normal to
early malignant transformation, but are critical for tumor pro-
gression and maintenance, since removal of FTase β after
DMBA/TPA initiation significantly reduced the number as well
as size of skin papillomas. The important finding that tumor pro-
gression is hampered by the lack of protein farnesylation pro-
vides proof-of-principle for the use of FTIs as chemopreventive
agents. Indeed, FTIs have been shown to be effective in mouse
lung cancer chemoprevention models (Lantry et al., 2000;
Zhang et al., 2003). One possible use for FTIs in prevention tri-
als is after surgical removal of tumors of lung and breast cancer
patients, where the incidence of recurrence is significant.
An important question that was not fully addressed by this
study and that requires further investigation is whether protein
farnesylation is required for tumors that are driven by H-Ras.
This is an important question, because unlike K-Ras, H-Ras is
exclusively farnesylated and is not alternatively geranylgerany-
lated when FTase is absent (Lerner et al., 1997; Rowell et al.,
1997; Whyte et al., 1997). Although H-Ras is reproducibly acti-
vated in the DMBA/TPA skin carcinogenesis mouse model, only
two-thirds of the papillomas contain mutant H-Ras (Balmain
and Pragnell, 1983), indicating that mutant H-Ras is not the only
contributor to the DMBA/TPA-induced tumors. An alternative
model that could more directly address the importance of pro-
tein farnesylation in H-Ras driven oncogenesis is one where the
FTase β (−/−) mice are crossed with the MMTV-H-Ras trans-
genic mice where mammary tumor formation is driven by
mutant H-Ras (Sun et al., 2003). Finally, Mijimolle et al. made an
intriguing observation that warrants further investigation. They
found that, in FTase β (−/−) MEFs, H-Ras is not farnesylated but
is associated with 100,000 × g pellets, suggesting that it is still
membrane-bound. This is an important finding that must be
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some patients respond to FTIs while others do not. While evalu-
ating FTIs either as single agents or in combination in various
clinical settings (i.e., early stages versus late stages of disease)
may improve response rates, it is clear that we know little about
how FTIs work, and that enhancing our knowledge of the mech-
anism by which FTIs inhibit proliferation and induce apoptosis
will result in great benefit to cancer patients (Zhu et al., 2003).
Among the most important questions that remain unanswered
concerning the mechanism of FTI mode of action are:
(1) Is the housekeeping enzyme FTase the only biochemical
target for FTIs? Are there other targets to FTIs that contribute to
their antitumor activity? If so, are these important to tumor sur-
vival only in those patients that respond to FTIs?
(2) If FTase is the biochemical target for FTIs, then which
FTase substrates are pivotal to malignant transformation (the
inhibition of farnesylation of which results in thwarting aberrant
signal transduction circuits that are important for tumor sur-
vival)? Are these farnesylated proteins only implicated in tumor
survival of those patients who respond to FTIs?
(3) How important is protein farnesylation in normal versus
tumor cells, and can we exploit the differences (if any) to avoid
toxicity and undesirable effects? If protein farnesylation is critical
to tumorigenesis, at what stage (initiation, progression, and/or
maintenance) are tumors addicted to protein farnesylation?
Answering these questions will have a major impact on
enhancing our ability to use FTIs in the prevention and/or thera-
py of cancer. In this issue of Cancer Cell, two reports help us get
closer to reaching this important goal. The first, by Mijimolle et
al. (2005), addresses in an elegant fashion the importance of
protein farnesylation in embryogenesis, postnatal development,
adult homeostasis, and tumorigenesis in mice. While much of
the work on the importance of protein farnesylation has relied
on chemical biology approaches using FTIs, this study used a
genetic approach by generating constitutive and conditional
knockout mice for the β subunit of FTase. The results clearly
demonstrate that the FTase β gene is essential for early embry-
onic proliferation, but dispensable for postnatal development
and adult homeostasis. Furthermore, this gene was not found to
be required for initiation of tumorigenesis in a K-Ras-dependent
lung tumorigenesis model or in a skin carcinogenesis model.
Importantly, however, the study demonstrated that the FTase β
gene is critical during tumor progression in the same chemical
skin carcinogenesis model. These key observations enhance
our understanding of the role of protein farnesylation in normal
physiology, tumor development, and cancer therapy and pre-
vention. First, the fact that mating FTase β (−/+) mice did not
yield homozygous embryos at embryonic stages E11.5 or older
due to decreased proliferation and increased apoptosis at E7.5,
coupled with the demonstration that FTase β (−/−) MEFs have
reduced proliferative activity and motility, confirms in a more
direct way the earlier observation that farnesylated proteins play
key roles in the cell division cycle, cytoskeleton organization,
migration, and survival (Sebti and Der, 2003). Second, except
for delayed wound healing and defects in erythroid cells, FTase
β (−/−) conditional knockout mice up to 18 months of age did not
show behavioral, anatomical, or pathological defects, suggest-
ing that protein farnesylation is dispensable for postnatal devel-
opment and adult homeostasis. This is somewhat surprising,
and leads one to wonder how an organism can survive with
potentially several hundred defective farnesylated proteins with
various important physiological functions. Possible ways by
which the organism could compensate for the loss of protein far-
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confirmed by showing by immunohistochemistry in whole cells
that H-Ras is still localized to the inner leaflet of the plasma
membrane. Furthermore, the mechanism by which this associa-
tion occurs is of great interest. What is puzzling about this find-
ing is that the C186S H-Ras mutant, which is not prenylated,
and H-Ras from FTI-treated cells are both cytosolic and not
membrane-bound (Lerner et al., 1995; Willumsen et al., 1984a;
Willumsen et al., 1984b).
The second article deals with the important issue of
whether targets other than FTase can contribute to the antipro-
liferative and proapoptotic effects of some FTIs. Using a chemi-
cal genetics approach, in the nematode c-elegans as a model,
Lackner et al. (2005) identified inhibition of RabGGTase as a
potential mechanism by which some FTIs can induce apopto-
sis. The authors demonstrated that certain FTIs from Bristol-
Myers Squibb that are potent inducers of apoptosis directly
inhibit the enzymatic activity of RabGGTase with potencies that
correlate well with their p53-independent proapoptotic activity.
The proapoptotic activity of FTIs was mimicked by knockdown
of RabGGTase as well as some of its substrates such as Rab5
and Rab7 that are involved in endosomal trafficking. Finally, the
authors also found that overexpression of both the α and β sub-
units of RabGGTase is prevalent in human tumor tissues, pro-
viding further proof-of-concept for RabGGTase as a novel target
for cancer drug discovery.
The findings of this second article have major implications
for identifying novel targets for cancer therapy. Furthermore, if
these findings can be extended to other FTIs, particularly to
those presently in clinical trials, this could lead to a better
understanding and interpretation of FTI clinical results. The first
major implication for cancer therapy is the identification of a
novel p53-independent pathway for inducing apoptosis in can-
cer cells. The authors provide strong evidence that demon-
strates that inhibition of RabGGTase, which results in blocking
the posttranslational modification of Rab proteins, leads to pro-
grammed cell death, suggesting that interfering with endosomal
trafficking pathways is a novel approach to cancer chemothera-
py. The authors’ elegant knockdown experiments of various
components of these pathways (i.e., Rab5 and Rab7), coupled
with recent reports of the involvement of endosomal Rab
GTPases in survival and proliferation of cancer cells, give fur-
ther validation for this concept. Although the GTPases Rab5
and Rab7 could be considered as targets for developing novel
proapoptotic anticancer drugs, RabGGTase is clearly a better
target for structure-based rational drug design, since its struc-
ture and biochemistry have been studied (Shen and Seabra,
1996; Thoma et al., 2001a; Thoma et al., 2001b; Zhang et al.,
2000). Furthermore, because of active site similarities with
FTase and GGTase I (Strickland et al., 1998; Zhang et al.,
2000), one can build on the extensive experience with the
design of FTase and GGTase I inhibitor to design selective
RabGGTase inhibitors (Reid and Beese, 2004). One drawback
of this approach, however, could be blood clotting problems and
retinal degeneration associated with inhibition of RabGGTase
(Seabra et al., 2002).
The other major implication of the findings by Lackner et al.
is that certain FTIs can potently inhibit RabGGTase, suggesting
that these compounds have targets other than FTase that con-
tribute to their antitumor activity, particularly their proapoptotic
activity. This is important since it demonstrates for the first time
that, though FTIs were designed/identified to inhibit selectively
FTase, they can recognize other targets; in this case, a related
prenyltransferase family member, RabGGTase. Furthermore, at
present, it is not known why some tumor cells (in culture in vitro
and in patients in vivo) are sensitive, whereas others are not.
The discovery that certain FTIs can potently inhibit RabGGTase
opens a new avenue to address this important question. It
would, therefore, be very important to determine whether there
is a correlation between the levels of expression of RabGGTase
α and β subunits and/or inhibition of RabGGTase and clinical
activities/toxicities seen in clinical trials. If this turns out to be the
case, then one could propose a mechanism of selection for
patients that would most likely respond to certain FTIs.
Although the findings of Lackner et al. are important, their
interpretations and implications must be accompanied by a cau-
tionary note. Clearly, further investigations are warranted to
establish how universal the findings are and whether they can
be extended to other unrelated FTIs. The important work
described in this article, as pointed out by the authors, was
prompted by the uniqueness of certain Bristol-Myers Sqibb
FTIs, particularly BMS-1, as strong inducers of apoptosis.
Although several FTIs have been evaluated by the authors, it is
not clear from this article whether this unique character of cer-
tain FTIs can be extended to other FTIs, particularly those that
have been extensively tested clinically. For example, if the clini-
cal responses and toxicities that have been determined to date
in the clinic are seen with FTIs that do not inhibit RabGGTase,
then biochemical correlative work with this enzyme would not
enhance our interpretations of clinical trial results as proposed
above. Therefore, it is pivotal that a thorough and systematic
evaluation of all known FTIs for their ability to inhibit
RabGGTase be performed prior to committing to these correla-
tions.
In summary, the articles by Mijimolle et al. and Lackner et al.
describe highly elegant studies that enhance our understanding
of the role of protein prenylation in embryogenesis, postnatal
development, adult homeostasis, tumorigenesis, and cancer
therapy and prevention. They have greatly advanced the field
and will have consequences on future directions for mechanistic
studies as well as investigations in clinic. The following are
some important questions that are prompted by these studies
and that warrant further investigations. What are targets other
than FTase that contribute to FTIs’ mode of action? Is
RabGGTase a universal target for FTIs, particularly those that
are in clinical trials? Can RabGGTase be a safe target for can-
cer therapy? Is protein farnesylation important for H-Ras-
dependent oncogenesis? What farnesylated proteins are
required for tumor progression and maintenance? Can FTIs be
used as chemopreventive agents?
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